Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), saw an insider increase his positioning with the company. Director Anthony E. Maida III acquired 3,466 shares of common stock at an average of $6.05 per share. Following this transaction, Maida now holds 28,373 shares directly in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), the $520.60 market cap corporation that is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology.
In addition, the two major hedge funds that have holdings in the company altered their positions recently. Millennium Management, the hedge fund run by Israel Englander, reported a rise of 26% in it’s activity last quarter, and now holds 4,703,190 shares worth about $36.8 million; while Deerfield Management, the hedge fund controlled by James E. Flynn, went the other direction, lowering it’s exposure to the company by 46% over the last quarter, and now has 1,265,375 shares worth nearly $10 million invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).
Disclosure: The author, Daniel Forstein, holds no positions in any stocks mentioned.